FACC AG

Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial.
PR Newswire; 11/16/2009; 1265 words; ...bioabsorbable technology," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief...tissue proliferation. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed...

Abbott's XIENCE PRIME(TM) and XIENCE V(R) Receive Indications in Europe for Treatment of Patients with Diabetes.
PR Newswire Europe; 11/2/2009; 1672 words; ...patients with diabetes," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief...the two companies. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed...

CHINA TAKES DOWN AUSTRALIAN COMPONENT GIANT FOR JUMBO PLAN
AsiaInfo Services; 10/9/2009; 371 words; ...agreed to acquire a 91.25% stake in FACC AG, a gigantic Australian aircraft component...consideration, but analysts assessed the whole FACC at about EUR 100 million. Anticipating...In the 2008-2009 fiscal years, FACC gained revenue of about EUR 277 million...

Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial.
PR Newswire; 8/13/2009; 1342 words; ...procedure," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical...trial along with Mitch Krucoff, M.D., FACC, FCCP, director, Cardiovascular Devices...Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor...

Abbott Announces EuroPCR 2009 Activities.
PR Newswire; 5/18/2009; 1190 words; ...real-world population," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief...xiencev.com/. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed...